GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (STU:24H) » Definitions » Valuation Rank

Hansa Biopharma AB (STU:24H) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is Hansa Biopharma AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Hansa Biopharma AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (STU:24H) » Definitions » Valuation Rank
Comparable Companies
OSTO:EGTX OSTO:VICO OSTO:GENO OSTO:XSPRAY OSTO:BINV OSTO:DMYD B OSTO:SYNACT XSAT:HAMLET B OSTO:SANION OSTO:MAGLE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
HNSA:Sweden 0RC7:UK
Address
Scheelevagen 22, Lund, SWE, 223 63
Website
https://www.hansabiopharma.com
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.